WHAT IS ONKO-SURE?
Onko-Sure™ is a simple, non-invasive blood test, which targets a cancer-caused breakdown product. Onko-Sure™ detects a tumor marker that is associated with most cancers. The biological target for the Onko-Sure™ test is abundant and floats-freely in blood (unlike Carcinoembryonic antigen, CEA). Biomarker levels rise dramatically with cancer progression (up to 38 times greater than in normal patients). Onko-Sure™ may become the first "pan tumor" marker in general widespread usage. Onko-Sure™ has international regulatory approvals as a general cancer marker in Taiwan, South Korea, Vietnam, India and Europe (CE Mark certification). In addition, Onko-Sure™ is approved for the detection and monitoring of lung cancer in Canada (Health Canada). In the US, Onko-Sure™ has been cleared to market as a colorectal cancer monitoring test.
Radient did not pay the annual fee to continue product registration with the FDA.
All patents for Onko Sure have now expired and the only patent application remaining has received a final rejection. The patent agent has resigned and there is no longer any current contact address for Radient Pharmaceuticals.
Telephone has been disconnected.
Radient-pharma.com website has been removed from service.
A website in Australia, Radient-diagnostics.com is pending under construction since May 6, 2014.
With penalties and interest, Radient still owes the 2011 lenders in excess of $25 million.